05:42 AM EDT, 04/28/2026 (MT Newswires) -- Peptonic Medical (PMED.ST) said Tuesday it finalized interim reports for its antibiotic-free self-care treatment Vernivia with its notified body, marking a key step toward updating the product's CE mark under the EU Medical Device Regulation.

The Swedish medical technology company added that CE marking is a key step to resume the sales of Vernivia, a patented product used to treat vaginal infections, which was previously approved under older rules.

Peptonic plans to relaunch the product by the end of 2026, with sales expected to begin in early 2027.